Clinical trial inspo: Online platform matches R&D to drugmakers

By Flora Southey contact

- Last updated on GMT

GettyImages/cyano66
GettyImages/cyano66
An online platform linking drugmakers with disease interventions could help pharma companies enter early phase trials, says IN-PART.

The platform – named IN-PART: Discover – is designed to enhance and accelerate university and industry collaboration.

“Discover was born out of feedback from our industry audience,” ​said IN-PART co-founder Robin Knight.

“Companies are looking for a proactive and resource-efficient way to seek out university collaboration opportunities fitting their own bespoke requirements, before anyone else,” ​he added.

Early-phase development

The platform benefits drug makers looking for new disease interventions, said Knight, who told us opportunities for pharmaceutical companies are usually in pre-clinical or early-phase development.

“Some companies are interested in reviewing the developmental spectrum of discoveries and opportunities in their R&D ​[research and development] interest area, whereas others want to focus purely on novel early-stage targets, or have specific essential requirements such as ​‘in vivo’ data, or ​‘clinical expertise’,” said Knight.

“Currently, there is no system able to engage university teams worldwide in a meaningful and scalable way with a company’s specific external R&D ‘wish list’, or technical challenge,” ​he added.

Industry/university engagement

According to the UK-based firm, alternative platforms on the market centralise information that is ‘trawled’ from databases and university websites, which can provide outdated data.

“This results in missing the latest innovation yet to be uploaded, or taking place in institutions that do not have the resources to maintain a public portal,”​ said Knight.

Similarly, platforms that promote industry challenges have little engagement with academic institutions, he said. “Usually they ​[these systems] are open to the public and only those proactive enough to be members provide content,” ​he told us.

IN-PART: Discover engages with universities worldwide including UK-based Oxford and Cambridge, and US universities Stanford and MIT, as well as smaller institutions.

Related news

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars